Views of Wockhardt's Manufacturing Facilities As Indian Pharmaceuticals Breach Quality Control

The movement of passing pedestrians and vehicles is seen as a cyclist travels along a road beside the Wockhardt Ltd. manufacturing facility in the Chikalthana industrial area in Aurangabad, India, on Monday, Sept. 16, 2013. Wockhardt currently controls about 26 percent of the U.S. market for metoprolol, a generic version of the heart pill sold by London-based AstraZeneca Plc under the brand name Toprol-XL, according to Needham & Co. Metoprolol alone makes up about 14 percent of the company's 56 billion rupees in annual revenue. Photographer: Dhiraj Singh/Bloomberg via Getty Images
The movement of passing pedestrians and vehicles is seen as a cyclist travels along a road beside the Wockhardt Ltd. manufacturing facility in the Chikalthana industrial area in Aurangabad, India, on Monday, Sept. 16, 2013. Wockhardt currently controls about 26 percent of the U.S. market for metoprolol, a generic version of the heart pill sold by London-based AstraZeneca Plc under the brand name Toprol-XL, according to Needham & Co. Metoprolol alone makes up about 14 percent of the company's 56 billion rupees in annual revenue. Photographer: Dhiraj Singh/Bloomberg via Getty Images
Views of Wockhardt's Manufacturing Facilities As Indian Pharmaceuticals Breach Quality Control
KÖP EN LICENS
Hur får jag använda den här bilden?
kr 4,200.00
SEK

INFORMATION

Begränsningar:
Kontakta ditt lokala kontor för all kommersiell eller marknadsföringsrelaterad användning.For editorial use only. Additional clearance required for commercial or promotional use, contact your local office for assistance. Any commercial or promotional use of Bloomberg content requires Bloomberg's prior written consent.
Upphovsman:
Bloomberg / Contributor
Redaktionell fil nr:
181967087
Samling:
Bloomberg
Datum skapat:
16 september 2013
Uppladdningsdatum:
Releaseinformation:
Saknar release. Mer information
Källa:
Bloomberg
Objektnamn:
INDIA WOCKHARDT